Page Title
Clinical Trial Finder
Ask About Participating in This Study
Restore CFTR ProteinClosed to Enrollment
Study of ABBV-3067 and ABBV-2222 in adults with cystic fibrosis who have two copies of the F508del mutation, protocol number AbbVie M19-530The following information will be used to determine eligibility for this study. Fill out the form and click “Preview Message.” This will draft an email you can send directly to the Research Coordinator. Please note, this does not guarantee entry into this particular study.
* indicates required field
Personal Information
Add more details about who you are and how you would like to be contacted (e.g. phone, text, email).
(this will open in your email program)
Restore CFTR ProteinClosed to Enrollment
Study of ABBV-3067 and ABBV-2222 in adults with cystic fibrosis who have two copies of the F508del mutation, protocol number AbbVie M19-530
This study will look at the safety and effectiveness of ABBV-3067, a CFTR modulator intended to help CFTR protein function closer to normal. ABBV-3067 will be tested alone and in combination with another CFTR modulator, ABBV-2222.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
5
-
Length of Participation:
3 months
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More